GeneHealth - Your precision medicine

Myxoedema

Disease Details

Family Health Simplified

Buy Membership

Description: Myxoedema is a severe form of hypothyroidism characterized by swelling of the skin and underlying tissues, resulting in a waxy appearance.
Type: Myxoedema is a severe form of hypothyroidism and is not typically associated with a specific type of genetic transmission. Hypothyroidism itself can have various causes, including autoimmune disorders like Hashimoto's thyroiditis, iodine deficiency, or can be present at birth (congenital hypothyroidism). While there can be a genetic predisposition to conditions like Hashimoto's thyroiditis, myxoedema as a condition does not follow a straightforward genetic transmission pattern.
Signs And Symptoms: Myxedema's characteristic physical sign is non-pitting edema, in contrast to pitting edema.Myxedema can also occur in the lower leg (pretibial myxedema) and behind the eyes (exophthalmos).
Severe cases, requiring hospitalization can exhibit signs of hypothermia, hypoglycemia, hypotension, respiratory depression, and coma.
Prognosis: Myxoedema, associated with severe hypothyroidism, has a generally good prognosis with appropriate treatment. However, untreated myxoedema can lead to life-threatening complications such as myxoedema coma, which has a high mortality rate. Overall, the long-term outlook improves significantly with early diagnosis and proper management of thyroid hormone levels.
Onset: Myxedema describes a severe form of hypothyroidism that can result in significant swelling of the skin and tissues, particularly in the face and lower legs. The onset is usually gradual, often developing over several months or years as hypothyroidism progresses. Hypothyroidism itself can occur at any age but is most common in middle-aged and older women. Symptoms may include fatigue, weight gain, cold intolerance, and depression. If left untreated, myxedema can lead to more severe complications, including myxedema coma, which is a medical emergency.
Prevalence: The prevalence of myxoedema is not clearly defined as "nan." Myxoedema, or severe hypothyroidism, is more common in older adults and women. Precise prevalence rates can vary based on the population and geographic area. For example, hypothyroidism, which can lead to myxoedema, affects about 4.6% of the U.S. population aged 12 and older.
Epidemiology: Myxoedema, which is a severe form of hypothyroidism, primarily affects middle-aged and older adults, with a higher prevalence in women than men. The epidemiology of hypothyroidism, including myxoedema, varies globally, but it is estimated to affect about 1-2% of the population in iodine-sufficient areas. The incidence increases with age, and certain populations, such as those with autoimmune thyroiditis (Hashimoto's thyroiditis), have a higher risk.
Intractability: Myxedema, a severe form of hypothyroidism, can often be managed effectively with appropriate medical treatment such as thyroid hormone replacement therapy. Therefore, it is not considered intractable. Proper diagnosis and consistent treatment usually lead to significant improvement or resolution of symptoms.
Disease Severity: Myxoedema, also known as severe hypothyroidism, is a serious and potentially life-threatening condition if left untreated. It requires prompt medical attention to manage hormone levels and prevent complications.
Healthcare Professionals: Disease Ontology ID - DOID:11634
Pathophysiology: Myxedema describes a specific form of cutaneous and dermal edema secondary to increased deposition of connective tissue components. The connective fibres are separated by an increased amount of protein and mucopolysaccharides. These can include glycosaminoglycans, such as hyaluronic acid, chondroitin sulfate and other mucopolysaccharides. This protein-mucopolysaccharide complex binds water, producing non-pitting boggy edema, in particular around eyes, hands, feet and in the supraclavicular fossae. Myxoedema is responsible for the thickening of the tongue and the laryngeal and pharyngeal mucous membranes, which results in thick slurred speech and hoarseness, both of which are seen commonly in hypothyroidism.
The increased deposition of glycosaminoglycan is not fully understood, however, two mechanisms predominate:

Fibroblast stimulation. It is thought that fibroblast stimulation by the thyroid stimulating hormone (TSH) receptor increases the deposition of glycosaminoglycan, which results in an osmotic edema and fluid retention. It is thought that many cells responsible for forming connective tissue react to increases in TSH levels.
Lymphocyte stimulation. In Graves' thyroid disease, lymphocytes react against the TSH receptor by inappropriately producing thyroid-stimulating immunoglobulin (IgG; type II hypersensitivity). Lymphocytes react not only against thyroid receptors, but also any tissue with cells expressing the receptor. This can lead to tissue damage and scar tissue formation, explaining the deposition of glycosaminoglycans.
Carrier Status: Carrier status is not applicable to myxedema. Myxedema is a severe form of hypothyroidism and is related to thyroid hormone deficiency rather than a condition that can be carried or transmitted genetically in a carrier state.
Mechanism: Myxedema is a severe form of hypothyroidism characterized by the accumulation of mucopolysaccharides in the skin and tissues, leading to swelling and thickening.

**Mechanism:**
Myxedema results primarily from inadequate levels of thyroid hormones, specifically thyroxine (T4) and triiodothyronine (T3). This deficiency leads to various physiological and biochemical changes in the body, including:

1. Decreased metabolism: Reduced thyroid hormone levels slow down the metabolic processes.
2. Accumulation of glycosaminoglycans (GAGs): Particularly hyaluronic acid and chondroitin sulfate, these substances build up in the interstitial spaces, attracting water and leading to the characteristic tissue swelling.

**Molecular Mechanisms:**
1. **Gene Expression:** Thyroid hormones are critical regulators of gene expression. Reduced levels of T3 and T4 lead to diminished activation of thyroid hormone receptors, impacting the transcription of numerous genes involved in metabolism, growth, and development.

2. **Enzymatic Activity:** Lower thyroid hormone levels decrease the activity of enzymes involved in energy production and turnover of cellular components, which contributes to the accumulation of GAGs.

3. **Protein Synthesis:** Thyroid hormones typically upregulate the synthesis of proteins that degrade GAGs. In their absence, GAGs are not broken down efficiently, causing them to accumulate in connective tissues.

4. **Water Retention:** The increased concentration of GAGs in the extracellular matrix binds more water, resulting in the characteristic non-pitting edema of myxedema.

5. **Reduced Cellular Metabolism:** Thyroid hormone deficiency impairs the function of sodium-potassium ATPase pumps, decreasing cellular energy expenditure and contributing to the overall reduction in metabolic rate, further enabling GAG accumulation.

These disruptions in normal physiological processes manifest as the clinical symptoms of myxedema, including swelling (especially in the face and extremities), weight gain, lethargy, and cognitive impairment.
Treatment: Myxoedema is a severe form of hypothyroidism that can be life-threatening. Treatment typically involves:

1. **Thyroid hormone replacement therapy**: Usually with levothyroxine to restore normal levels of thyroid hormone.
2. **Corticosteroids**: To treat possible adrenal insufficiency.
3. **Supportive care**: Addressing symptoms and complications, such as maintaining stable body temperature, monitoring heart function, and treating any infections.
4. **Monitoring**: Regular follow-up appointments to adjust medication dosage and ensure thyroid levels remain stable.

It is crucial for individuals with myxoedema to receive prompt medical attention.
Compassionate Use Treatment: For myxedema, which is severe hypothyroidism, the primary treatment is levothyroxine to replace thyroid hormone. Compassionate use treatments or experimental treatments for myxedema are not typically the focus since conventional treatment with thyroid hormone replacement is effective. However, in certain cases where standard treatments are not effective or available, experimental therapies might be considered under clinical trials. Off-label adjunct treatments might include the use of corticosteroids if adrenal insufficiency is suspected alongside the hypothyroidism. Always consult a healthcare provider for the most appropriate and current treatment options.
Lifestyle Recommendations: For myxoedema (severe hypothyroidism), lifestyle recommendations include:

1. **Medication Adherence**: Take prescribed thyroid hormone replacement medications (like levothyroxine) consistently and as directed by your healthcare provider.

2. **Regular Monitoring**: Schedule regular check-ups to monitor thyroid hormone levels and adjust medication dosage if needed.

3. **Balanced Diet**: Eat a healthy, balanced diet rich in fruits, vegetables, whole grains, and lean proteins. Ensure adequate intake of iodine, selenium, and zinc, which are essential for thyroid function.

4. **Physical Activity**: Engage in regular physical activity to help maintain a healthy weight and improve overall well-being. However, consult your healthcare provider before starting any new exercise regimen.

5. **Stress Management**: Practice stress-reducing techniques such as yoga, meditation, or deep breathing exercises to support overall health.

6. **Avoiding Hypothyroid Triggers**: Limit or avoid foods and substances that can interfere with thyroid function, such as soy products, highly processed foods, and excessive caffeine.

7. **Adequate Sleep**: Prioritize getting enough restful sleep each night to support thyroid health and overall wellness. Aim for 7-9 hours of sleep per night.

8. **Hydration**: Drink plenty of water to stay hydrated and support metabolic processes.

Consult with your healthcare provider for personalized advice.
Medication: Myxoedema, often associated with severe hypothyroidism, is treated primarily with synthetic thyroid hormone replacement. The standard medication is levothyroxine, which is a synthetic form of the thyroid hormone thyroxine (T4). Levothyroxine is taken orally and helps to restore normal hormone levels, alleviating symptoms of hypothyroidism such as fatigue, weight gain, and cold intolerance. Dosage and treatment plans should be supervised and regularly monitored by a healthcare provider to ensure effective management of the condition.
Repurposable Drugs: Repurposable drugs for myxedema (severe hypothyroidism) could include the following:

1. **Levothyroxine**: Although it's the standard treatment, optimizing its dosage can help manage myxedema effectively.
2. **Liothyronine**: In some cases, adding liothyronine (T3) to levothyroxine (T4) therapy might be beneficial.
3. **Metformin**: Primarily used for type 2 diabetes, it has shown some potential in improving thyroid function and may be considered in hypothyroid patients with metabolic syndrome.

Further research is needed to validate the efficacy and safety of these repurposed drugs in managing myxedema.
Metabolites: Myxoedema, also known as severe hypothyroidism, is associated with altered metabolism due to decreased thyroid hormone levels. This can lead to the accumulation of glycosaminoglycans (mucopolysaccharides) in the skin and other tissues, resulting in the characteristic swelling. Other metabolic changes include increased cholesterol and triglyceride levels, and decreased activity of various metabolic enzymes.
Nutraceuticals: Nutraceuticals are not a primary treatment for myxoedema, which is a severe form of hypothyroidism. Myxoedema typically requires thyroid hormone replacement therapy prescribed by a healthcare professional. Additionally, there is no well-established evidence to support the use of nutraceuticals in the treatment of myxoedema.
Peptides: Myxoedema refers to a severe form of hypothyroidism. It is characterized by the accumulation of mucopolysaccharides in the skin and other tissues, leading to swelling and thickening. There isn't a specific peptide associated with myxoedema. Treatment often involves thyroid hormone replacement therapy, commonly using synthetic thyroid hormones like levothyroxine, rather than peptides. Nanotechnology is not typically involved in the standard treatment for myxoedema.